<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01584726</url>
  </required_header>
  <id_info>
    <org_study_id>#12095/12</org_study_id>
    <nct_id>NCT01584726</nct_id>
  </id_info>
  <brief_title>Nebulized Magnesium Sulfate in Children With Moderate to Severe Asthma</brief_title>
  <official_title>Nebulized Magnesium Sulfate in Children With Moderate to Severe Asthma Exacerbation: A Randomized, Double-Blind, Controlled Trial (RCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hamad Medical Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hamad Medical Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the use of magnesium sulfate nebulization in
      patient with moderate to severe asthma exacerbation in pediatric emergency.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      the use of magnesium sulfate nebulization in patient with moderate to severe asthma
      exacerbation in pediatric emergency

      follow asthma severity score and length of stay
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Would the use of nebulized magnesium sulfate in patients with moderate to severe asthma significantly reduce the time to clinical readiness for discharge?</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>â€¢ Would the use of nebulized magnesium sulfate in patients with moderate to severe asthma decrease admission and readmission rate, compared to placebo</measure>
    <time_frame>36 months</time_frame>
    <description>Would the use of nebulized magnesium sulfate in patients with moderate to severe asthma decrease PICU admission rate, compared to placebo?
Would the use of nebulized magnesium sulfate in patients with moderate to severe asthma improve change in asthma severity score at 4, 8, 12 hours, compared to placebo?
Would the use of nebulized magnesium sulfate in patients with moderate to severe asthma decrease return rate to emergency services, compared to placebo?
Would the use of nebulized magnesium sulfate in patients with moderate to severe asthma decrease rate of infirmray admission in follow up, compared to placebo?</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>magnesium sulfate arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>magnesium sulfate with standard therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>placebo with standard therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium Sulfate</intervention_name>
    <description>single dose of magnesium sulfate nebulization</description>
    <arm_group_label>magnesium sulfate arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pediatric asthma patients with moderate to severe exacerbation

        Exclusion Criteria:

          -  Known allergy to magnesium sulfate

          -  History of neuromuscular disease, cardiac disease, renal disease, or underlying
             chronic lung disease

          -  Use of oral steroid medication within 72 hours of presentation

          -  Radiographic evidence of pneumonia at presentation

          -  Administration of intravenous magnesium sulfate prior to study enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>KHALID AL ANSARI, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SENIOR CONSULTANT-HEAD OF PEDIATRIC EMERGENCY</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dr. Khalid Al Ansari, MD,FRCP,FAAP</last_name>
    <phone>97444396001</phone>
    <phone_ext>6006</phone_ext>
    <email>dkmaa@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dr. Wessam Mouharam, MD</last_name>
    <phone>97444396022</phone>
    <phone_ext>6012</phone_ext>
    <email>wessam_mouharam@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hamad Medical Corporation</name>
      <address>
        <city>Doha</city>
        <zip>3050</zip>
        <country>Qatar</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>KHALID AL ANSARI, MD,FRCP,FAAP</last_name>
      <phone>+974 44396006</phone>
      <phone_ext>6001</phone_ext>
      <email>dkmaa@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>WESSAM MOUHARAM, MD</last_name>
      <phone>+97444396022</phone>
      <phone_ext>6012</phone_ext>
      <email>wessam_mouharam@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Dr,KHALID AL ANSARI, MD,FRCP,FAAP</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>WESSAM MOUHARAM, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pediatric Emergency Centre</name>
      <address>
        <city>Doha</city>
        <zip>3050</zip>
        <country>Qatar</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>KHALID AL ANSARI, MD,FRCP,FAAP</last_name>
      <phone>97444396022</phone>
      <phone_ext>6006</phone_ext>
      <email>dkmaa@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>WESSAM MOUHARAM, MD</last_name>
      <phone>9744396022</phone>
      <phone_ext>6012</phone_ext>
      <email>wessam_mouharam@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>KHALID AL ANSARI, MD,FRCP,FAAP</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>WESSAM MOUHARAM, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Qatar</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2012</study_first_submitted>
  <study_first_submitted_qc>April 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2012</study_first_posted>
  <last_update_submitted>January 27, 2014</last_update_submitted>
  <last_update_submitted_qc>January 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>magnesium</keyword>
  <keyword>nebulization</keyword>
  <keyword>asthma</keyword>
  <keyword>sulfate</keyword>
  <keyword>children</keyword>
  <keyword>pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

